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Background
Raynaud’s phenomenon (RP) is a cold- or stress-triggered
digital ischemia caused by vasoconstriction in the digital
blood vessels, severely affecting patient’s life. Medical thera-
peutic options for RP are limited and commonly unsatisfac-
tory, with a large number of patients not responding to
currently available treatment. In the present study we inves-
tigated the safety, efficacy and pharmacokinetics of a single
dose of the soluble guanylate cyclase (sGC)-stimulator rio-
ciguat in patients with RP in a double-blind, randomized,
placebo-controlled cross-over fashion.
Methods and study population
Twenty patients with primary or secondary RP associated
with systemic sclerosis (SSc), and symptom duration of ≥1
year, were randomized to receive a single oral dose of 2
mg riociguat or placebo in a cross-over fashion (first visit,
1 week washout-phase, second visit). Patients and investi-
gators were blinded for the study medication at both visits
(cross-over). Digital blood flow (DBF) in the right index
finger was determined by Laser Speckle Contrast Analysis
at room temperature (RT) and 5 minutes after cold water
exposure (CWE), both at baseline and 2 hours after study
drug administration.
Results
In the overall study population, riociguat led to an
increase in DBF versus baseline of 40.6% at RT and
15.1% after CWE. Based on predefined criteria, patients
were considered responders if the placebo-corrected DBF
after CWE increased by ≥10% versus baseline at 2 hours
after drug intake. This was the case in 12/20 (60%)
patients. The highest response rates were seen in patients
with primary RP and limited cutaneous SSc, whereas
patients with RP associated with diffuse cutaneous SSc
responded less well. In responders, riociguat led to an
increase in DBF versus baseline of 135.7% at RT and
38.9% after CWE. Riociguat Cmax (±SD) 2 hours after
drug intake was 76 ±1.5 μg/ml, which is in the range pre-
viously seen in healthy volunteers and patients with pul-
monary hypertension. Comparable Cmax values were
observed in responders (81 ±1.5 μg/ml) and non-respon-
ders (71 ±1.6 μg/ml). AEs were reported in 5 patients
receiving riociguat (headache, n=4; dyspepsia, n=1) and 1
patient after placebo intake (malaise). No serious AEs
were reported.
Conclusion
The sGC-stimulator riociguat substantially improved
DBF in 60% of patients after cold exposure compared to
placebo. It was well tolerated in patients with primary
and secondary RP. The results of this study indicate that
a longer-term trial investigating the therapeutic effect of
riociguat in primary and secondary RP is warranted.
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